Pipeline
Our Clinical Trials
Our lead candidate is NXC-201, a BCMA-targeted CAR-T NXC-201 in Phase 1b/2a clinical trials (NEXICART-1 – NCT04720313) in relapsed/refractory AL Amyloidosis and relapsed/refractory multiple myeloma which has treated 72 patients
Our tissue specific therapeutic IMX-110 is currently in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 – IMMINENT-01 NCT05840835) for advanced solid tumors which has treated 30 patients
NXC-201 CELL THERAPY PUBLICATIONS
TSTx Publications
Clinical Trials
- IMX-110 Phase 1b/2a Trial: IMX-110 in Patients With Advanced Solid Tumors
- Select IMX-110 Development Safety Update Report (DSUR) Summary
- IMX-110 + Tizleilizumab anti-PD-1 Phase 1b/2a Trial: Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)
Scientific Posters, Publications & Reviews
- Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles In vitro evaluation on 2D and 3D tumor models
- A nanomedicine-based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation in 2D and 3D tumor models
- Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin
- Nanotechnology-based treatment for chemotherapy-resistant breast cancer
- Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies
- Constitutive Activation of NF-kB during Progression of Breast Cancer to Hormone-Independent Growth
- Development of Curcumin as an Epigenetic Agent
- Micellar Nanocarriers: Pharmaceutical Perspectives
- Cycling cancer persister cells arise from lineages with distinct programs
- Leveraging and coping with uncertainty in the response of individual cells to therapy
- IMX-110 Preclinical Data Pack (Oct 2021)
- IMX-120 Preclinical Data Pack (Oct 2021) (Undisclosed)
IMX-111 Preclinical Data Pack (Oct 2021)